Key result
Novel multi-biomarker panel diagnoses ischemic heart disease with high accuracy, achieving an AUC of ~0.89.
Why the study?
Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) are emerging mediators of atherogenesis, and this study evaluated their diagnostic utility and interrelationships alongside novel and traditional biomarkers in ischemic heart disease.
Does a multi-marker panel combining serum anti-apoA-1 IgG, IL-6, and ox-LDL improve the diagnostic accuracy for ischemic heart disease compared to individual biomarkers in patients with stable angina pectoris and acute myocardial infarction?
Cross-Sectional (n=280)
No
Does a multi-marker panel combining serum anti-apoA-1 IgG, IL-6, and ox-LDL improve the diagnostic accuracy for ischemic heart disease compared to individual biomarkers in patients with stable angina pectoris and acute myocardial infarction?
Serum anti-apoA-1 IgG levels are significantly elevated in ischemic heart disease—particularly in acute myocardial infarction—and combining anti-apoA-1 IgG with IL-6 and ox-LDL significantly improves diagnostic accuracy (AUC 0.89) over single biomarkers.
Answers are grounded in this paper and cite their sources.
May aid ischemic heart disease diagnosis; leaves open clinical utility pending prospective validation.
Background: Ischemic heart disease (IHD) involves complex inflammatory and immune-mediated processes. Autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) are emerging mediators of atherogenesis. This study aimed to profile serum anti-apoA-1 IgG alongside a panel of novel and traditional biomarkers to evaluate their diagnostic utility and interrelationships in IHD. Methods: This cross-sectional study enrolled 280 participants: 100 with stable angina pectoris (SAP), 100 with acute myocardial infarction (AMI), and 80 healthy controls. Serum levels of anti-apoA-1 IgG, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), and oxidised LDL (ox-LDL) were measured. Standard lipid profiles were also assessed. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Serum anti-apoA-1 IgG levels were significantly higher in both IHD patient groups compared to the control group (p<0.001), with AMI patients having higher levels than SAP patients (p<0.01). Furthermore, all biomarkers associated with inflammation and oxidative stress (hs-CRP, IL-6, Lp-PLA2, MPO, ox-LDL) were elevated in IHD patients. Anti-apoA-1 IgG showed a significant positive correlation with IL-6 (r=0.51, p<0.001) and MPO (r=0.45, p<0.001). In ROC analysis using multiple biomarkers, the combination of anti-apoA-1 IgG, IL-6, and ox-LDL yielded an AUC of 0.89 (95% CI: 0.85-0.93) for the diagnosis of IHD. Conclusion: Anti-apoA-1 IgG was significantly higher in IHD patients, especially in the acute phase of the disease, and was associated with markers of inflammation and oxidative stress. The inclusion of multiple markers, such as anti-apoA-1 IgG, IL-6, and ox-LDL, improves the diagnostic performance for ischemic heart disease. This approach yielded better diagnostic accuracy than using each marker individually.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2026) conducted a cross-sectional in Ischemic heart disease (stable angina pectoris and acute myocardial infarction) (n=280). Multi-biomarker panel (serum anti-apoA-1 IgG, IL-6, and ox-LDL) vs. Healthy controls / individual biomarkers was evaluated on Diagnostic accuracy for distinguishing ischemic heart disease (SAP + AMI) from healthy controls (AUC 0.89, 95% CI 0.85–0.93, p=<0.05). A multi-biomarker panel combining serum anti-apoA-1 IgG, IL-6, and ox-LDL achieved an AUC of 0.89 (95% CI: 0.85–0.93) for diagnosing ischemic heart disease, outperforming individual markers.
Synapse has enriched 10 related papers. Consider them for comparative context: